Mahammed LL, Vrtala S, Akinfenwa O et al. EBioMedicine. 2026 Sep 24:106484. doi: 10.1016/j.ebiom.2026.106484.
Allergy, Asthma and Immunology
A blog that publishes updates and open access scientific papers about allergy, asthma and immunology. Editor: Juan Carlos Ivancevich, MD. Specialist in Allergy & Immunology
September 29, 2026
Age-related molecular IgE sensitization to indoor and outdoor respiratory allergens: a two-step cross-sectional study in Algeria and Türkiye
September 28, 2026
Moderate-to-severe chronic spontaneous urticaria is associated with increased risk of immune-mediated diseases: A population-based study
Abstract
| Forest plot showing odds ratios (ORs) and 95% confidence intervals for immune-mediated comorbidities among patients with chronic spontaneous urticaria (CSU). |
Comparison of subcutaneous (SCIT) and sublingual (SLIT) immunotherapy in allergic rhinitis and allergic asthma
Abstract
Allergic rhinitis and allergic asthma are among the most prevalent chronic diseases, significantly impairing patients’ quality of life and generating substantial healthcare costs. Allergen immunotherapy (AIT), administered as subcutaneous (SCIT) or sublingual (SLIT) immunotherapy, remains the only treatment capable of modifying the natural course of allergic disease. The aim of this study was to compare the clinical efficacy, safety profile, adherence, and economic aspects of both AIT modalities based on current evidence. A narrative review of randomised clinical trials, meta-analyses, observational studies, and pharmacoeconomic analyses was conducted, with particular emphasis on treatment effectiveness, safety, adherence, and direct and indirect healthcare costs.
September 27, 2026
Advances in the role of house dust mite allergen components in the pathogenesis of allergic diseases
Guo CF, Wang Y, Wang YN et al. J Microbiol Immunol Infect. 2026 Sep 17:S1684-1182(26)00125-8. doi: 10.1016/j.jmii.2026.09.009.
Abstract
![]() |
| HDM allergen-induced epithelial barrier disruption and inflammatory signaling. |
September 23, 2026
Comprehensive 17-Allergen Panel for Inhalant Specific IgE: Reliability and Validation of Optimized Quantitative Assays
Ianniello A, Amadsun DO, Bencini E et al. Int Arch Allergy Immunol. 2026 Sep 21:1. doi: 10.1159/iaa/adfag015.
Abstract
Introduction: Atopic diseases, such as asthma and allergic rhinitis, are chronic inflammatory disorders mediated by immunoglobulin E (IgE) responses to environmental allergens. Detecting allergen-specific IgE is essential for diagnosing sensitization and guiding clinical management. Allergen-specific IgE assays have, thus, become indispensable in clinical diagnostics and allergy research. The CHORUS Specific IgE Capture assays are automated immunoassays designed to quantify up to 17 allergen-specific IgE antibodies in human serum. In this study, optimized versions of the assays have been evaluated to determine their analytical performance in terms of sensitivity, specificity, precision, and overall reliability.
September 22, 2026
Vaccines for Cancer: A Translational Science Review
ML, Chun BMN, Dhillon KK et al. JAMA. Published online September 21, 2026. doi:10.1001/jama.2026.15540
Abstract
Importance Advances in tumor immunology and vaccine technology are reshaping cancer vaccine development after decades of limited clinical success. More than 2000 immunogenic tumor proteins or antigens have been identified, the types of immune responses required for tumor eradication have been defined, and safe and effective vaccine delivery technologies have been developed. This progress has renewed clinical investigation of cancer vaccines for multiple types of cancer.
Observations Vaccines, such as those against human papillomavirus and hepatitis B, are composed of (1) an antigen target, (2) an adjuvant to activate the immune system, and (3) a vaccine delivery vehicle. Antigens can be derived from tumor mutations termed neoantigens, or cancer-associated nonmutated proteins, which are normal human proteins that are abnormally expressed in cancer. The tumor can also act as an antigen source, such as when immunization occurs with whole tumor cells or by directly injecting an immunogenic substance into the tumor to elicit an adaptive immune response. T and B lymphocytes, cells of the adaptive immune system, are stimulated by cancer vaccines and can provide a highly specific and durable immune response directed against cancer.
September 18, 2026
Nasal Epithelial Immune Signatures Are Associated With Age-Dependent Asthma Trajectories in Early Life
Jakwerth CA, Illi S, Charles H et al. Allergy. 2026 Sep 6. doi: 10.1111/all.70477.
ABSTRACT
Background
Preschool wheeze is heterogeneous and only a subset of children progresses to persistent asthma. We hypothesized that early-life wheeze reflects divergent airway epithelial maturation trajectories associated with distinct mucosal immune programs.
Methods
Nasal epithelial transcriptomes from 265 children and young adults (79 healthy, 81 wheezers, 105 asthmatics; median age 10.4 [1.1–20.3] years) from the All Age Asthma Cohort (ALLIANCE) cohort were analyzed using a hypothesis-driven candidate approach based on predefined cytokine axes. Transcriptional signatures were mapped to epithelial cells by scRNA-sequencing. Asthma-outcome associations were assessed in age- and sensitization-adjusted multivariate models.
Results
| Graphical Abstract |
September 17, 2026
Sublingual allergen immunotherapy: evidence from randomized trials, real-world studies and meta-analyses
Paoletti G, Valli N, Di Bona D et al. (2026) Front. Allergy 7:1940709. doi: 10.3389/falgy.2026.1940709
Abstract
Background:
Allergen immunotherapy is the only potentially disease-modifying treatment for IgE-mediated respiratory allergy. Among the available routes, sublingual immunotherapy (SLIT) has gained prominence because of its favorable safety profile and greater patient acceptability.
Objectives:
This narrative review critically appraises the clinical efficacy, real-world effectiveness, and long-term disease-modifying potential of SLIT for seasonal and perennial respiratory allergies by integrating evidence from randomized controlled trials, large observational cohorts, and meta-analyses, with attention to allergen- and product-specific outcomes and age-related differences.
Results:
Robust RCT evidence supports clinically meaningful reductions in symptoms and medication use with grass and HDM SLIT tablets, with sustained benefits observed up to 1–2 years after a 3-year treatment course in key trials.






